Protocol 1D93-008 
Page 17 
REFERENCES 
1. Boring CC. Squires TS. and Tong T. Cancer statistics. Ca 43:7-26, 1993. 
2. Louie KG, Ozols RF, Myers CE. Ostchega Y, Jenkins J. Howser D. and Young RC. Long- 
term results of a cisplatin-containing combination chemotherapy regimen for the treatment 
of advanced ovarian carcinoma. J Clin Oncol 4:1 579- 1585, 1986. 
3. Halnsworth JD. Grosh WW, Burnett LS. Jones HW, Wolff SN, and Greco FA. Advanced 
ovarian cancer Long-term results of treatment with intensive cisplatin-based chemotherapy 
of brief duration. Ann Jntem Med 108:165-170, 1988. 
4. Ozols RF, RC Young. Ovarian Cancer in: Current Problems in Cancer 1 1:57-122, 1987. 
5. Klrmanl S, Lucas WE, Kim S, Goel R, McVey L, Morris J, Howell SB. A phase II trial of 
tntraperltoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian 
carcinoma. J Clin Oncol 9:649-657, 1991. 
6. Rosenberg SA. Immunotherapy of patients with advanced cancer using interleukin-2 alone 
or In combination with lymphokine-actlvated killer cells. Chapter 12. pp. 217-257. In 
Irnportant Advances in Oncology 1988 V. T. Devita, S. Heilman, and S. A. Rosenberg, Eds. J. 
B. Uppincott, Philadelphia. 
7. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Line WM, Robertson 
CVN, Lee RE, Rubin JT, Seipp CA, Simpton CG, and White DE. A progress report on the 
treatment of 157 patients with advanced cancer using l 3 anphoklne-activated killer cells and 
lnterleukin-2 or high-dose interleukin-2 alone. N E^iglJ Med 3 16:889-897, 1987. 
8. Fisher RI, Coltman CA, Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, Wlemik P, 
McMannls JD, Weiss GR, Margolin K, Gemlo NT, Hoth DF, Parkinson DR, Paietta E. 
Metastatic renal cancer treated with interleukin-2 and lymphokine activated killer cells: A 
phase II clinical trial. Ann Intern Med 108:518-523, 1988. 
9. Steiss RG, Urba WJ, VanderMolen LA, et al. Intraperitoneal lymphokine-actlvated killer-cell 
and interleukin-2 therapy for malignancies limited to the peritoneal cavity. J Clin Oncol 
8:1618-1629, 1990. 
10. Stewart JA, Belinson JL, Moore AL, et al. Phase I trial of intraperitoneal recombinant 
lnterleukln-2/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Res 
50:6302-6310, 1990. 
11. Sznol M, Dutcher JP, Atkins MB, Rayner AR, Margolin KA, Gaynor ER, Weiss GR, Aronson 
F, Parkinson DR, Hawkins MJ. Review of interleukin-2 alone and interleukin-2/LAK clinical 
trials in metastatic malignant melanoma. Cancer Treat Rev SuppL A (June) p. 29-38, 1989. 
12. Topallan SL, Solomon D, Avis FP, Chang AE, Linehan WM, Lotze MT, Robertson CN, Seipp 
CA, Simon P, Simpson CG, and Rosenberg SA. Immunotherapy of patients with advanced 
cancer using tumor infiltrating l 3 miphocytes and recombinant IL-2 and a pilot study. J Clin 
Oncol 6:839-853, 1988. 
13. Aokl Takakuwa K, Kodama S, Tanaka K, Takahashi M, Tokunaga A, Takahashi T. Use of 
adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin 
containing chemotherapy in patients with epithelial ovarian cancer. Cancer Res 51:1934- 
1939, 1991. 
14. loannides CG, Freedman RS, Platsoucas CD, Kim Y-P. Cytotoxic T cell clones isolated from 
ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous 
tumor cells. J Immunol 146:1700-07, 1991. 
15. loannides CG,, Platsoucas CD. Rashed S, Wharton JT. Edwards CL. Freedman RS. Tumor 
cytolysis by l 3 nmphocytes infiltrating ovarian malignant ascites. Cancer Res 51:4257-65, 
1991. 
16. Freedman RS, loannides CG, Mathioudakis G, Platsoucas CD. Novel immunologic strategies 
in ovarian carcinoma. Am J Obstet GynecoL 167:1470-78, 1992. 
17. Freedman RS. Tomasovic B. Templin S. Atkinson EN, Kudelka A, Edwards CL, Platsoucas 
CD. Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients 
with ovarian carcinoma for adoptive immunotherapy. J Immunol Methods 167:145-60. 1994. 
[475] 
Recombinant DNA Research, Volume 19 
